Context Therapeutics' CTIM-76 Delivers 29% ORR and 57% Disease Control in Platinum-Resistant Ovarian Cancer
CNTX•Context Therapeutics reported a 29% overall response rate in platinum-resistant ovarian cancer treated with CTIM-76, with disease control in 57% and partial responses lasting at least six months. Safety profile included only Grade 1 cytokine release syndrome in 11% of patients and supports Q3W dosing exploration.
1. Interim Efficacy Data
As of the May 29 data cutoff, seven efficacy‐evaluable platinum-resistant ovarian cancer patients treated at 140–280µg doses achieved a 29% confirmed partial response rate and a 57% disease control rate, with three patients maintaining response or stable disease for at least six months.
2. Safety and Tolerability
CTIM-76 at active dose levels produced mostly Grade 1–2 adverse events that were reversible with standard management, with only one instance of Grade 1 cytokine release syndrome (11% of PROC patients), suggesting potential for outpatient administration.
3. Pharmacokinetics and Development Plan
Pharmacokinetic data showed dose-dependent exposure increases supporting a shift from weekly to every-three-week dosing in second-half 2026, while CTIM-76 holds FDA Fast Track designation and is slated for Phase 1b dose expansion in 2027.
